Interest of alpha2-adrenergic agonists and antagonists in clinical practice: background, facts and perspectives.
about
Norepinephrine and stimulant addictionIdentification of a novel snake peptide toxin displaying high affinity and antagonist behaviour for the α2-adrenoceptors.Alpha 2A adrenergic receptor agonist, guanfacine, attenuates cocaine-related impairments of inhibitory response control and working memory in animal models.The potential contribution of stress systems to the transition to chronic whiplash-associated disorders.β2-Adrenoreceptors of regulatory lymphocytes are essential for vagal neuromodulation of the innate immune system.Rubus occidentalis alleviates hyperalgesia induced by repeated intramuscular injection of acidic saline in ratsPlasma Norepinephrine in Hypertensive Rats Reflects α(2)-Adrenoceptor Release Control Only When Re-Uptake is InhibitedTyramine Reveals Failing α2-Adrenoceptor Control of Catecholamine Release and Total Peripheral Vascular Resistance in Hypertensive Rats.Evaluation of Oral Tiazinidine Effects on [intraoperative] Hemodynamic Responses During Direct Laryngoscopy Under General Anesthesia.Sympathetic overstimulation during critical illness: adverse effects of adrenergic stress.Pharmacologic options for reducing the shivering response to therapeutic hypothermia.Are the pharmacology and physiology of α₂ adrenoceptors determined by α₂-heteroreceptors and autoreceptors respectively?Quinoxaline derivatives: a patent review (2006--present).A polyspecific drug/proton antiporter mediates diphenhydramine and clonidine transport at the mouse blood-retinal barrier.Prevention of recurrent autonomic dysreflexia: a survey of current practice.Pharmacokinetic profile and pharmacodynamic effects of romifidine hydrochloride in the horse.
P2860
Q24656833-0F5978B2-CA78-4CFB-BAAE-2597A934ED5DQ34399307-80D6504B-FDC7-45A9-A51C-1B36BC1F5830Q35120282-13B8A6B0-28E5-4E05-89A2-6E71539BB15BQ35597060-FA057D24-40DB-4136-B3A3-3E190AE4ACD7Q35609622-66333AA4-559F-40F5-8C24-F09A465189DCQ36072849-2A41BF98-2258-46E4-9779-D57DF624856DQ36382594-ACDC3573-4835-4A1F-B705-43C32BDDA27DQ36644682-13B34FA6-70FE-4EE5-8565-38925481B404Q37411554-457FBBAF-509E-4277-9659-59ADE14478D4Q37585835-B8EB67EA-FC84-4883-A989-582F5DACAF66Q37775008-26D62C1A-4F22-402C-9905-F7D09B81C777Q37887038-5F9BAE99-C978-4245-A1E8-AA356A464C64Q38042737-793C64C7-FB5A-420D-8B79-626054B220C2Q41295446-9A3DD82E-3F48-4C19-93DA-6916D5AB2A4BQ41477135-38B7E5A1-75CE-4F1C-BEEE-5839FEE3C869Q45899328-A9B9F8F2-3D0F-475F-89F6-F9FD5AC9B1C9
P2860
Interest of alpha2-adrenergic agonists and antagonists in clinical practice: background, facts and perspectives.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
name
Interest of alpha2-adrenergic ...... round, facts and perspectives.
@ast
Interest of alpha2-adrenergic ...... round, facts and perspectives.
@en
type
label
Interest of alpha2-adrenergic ...... round, facts and perspectives.
@ast
Interest of alpha2-adrenergic ...... round, facts and perspectives.
@en
prefLabel
Interest of alpha2-adrenergic ...... round, facts and perspectives.
@ast
Interest of alpha2-adrenergic ...... round, facts and perspectives.
@en
P2093
P1476
Interest of alpha2-adrenergic ...... round, facts and perspectives.
@en
P2093
Colette Denis
Hervé Paris
Jean Michel Sénard
Pierre-Antoine Crassous
P304
P356
10.2174/156802607779318190
P577
2007-01-01T00:00:00Z